variant-preferred lines for use as unaffected controls in specific disease settings. CMs in 48-well plates were recorded over 20 second sweeps every three hours for ~25 3 days after reseeding (Fig. 2G ). Contractility of CMs was evaluated via impedance 4 readouts as beats per minute (bpm) and beating amplitude (BAmp) defined as the cell 5 index value between lowest and highest points within a beat waveform. Beat rate 6 averaged 36 bpm (range 32 to 49 bpm) with average amplitude 0.04 arbitrary units (AU) 7 (range 0.027 to 0.05 AU). Extracellular field potential spike amplitudes defined as the 8 difference between the lowest and highest recorded voltages ranged from 0.12 to 0.55 9 mV. These experiments demonstrate differentiation of three PGPC lines into beating 1 0 cardiomyocytes and highlight the potential value of using PGPC17 for CRISPR gene 1 1 editing for cardiac disease modeling. For endodermal differentiation we generated hepatocyte-like cells (HLC) using a by immunostaining for AFP, ALB, CYP3A7, and HNF4A ( Fig. 3D ). Measuring functional 2 5 activity of HBs (D14) and HLCs (D25) was performed using a p450-glo assay 2 6 (Promega). As expected, HLCs had significantly more enzymatic activity of both 2 7 CYP3A4 and CYP3A7 as measured by luminescence as compared to HBs. Treatment with 1 µM ketoconazole inhibited enzymatic activity of CYP3A7 to levels observed in 2 9
HBs (Fig. 3E ). These results demonstrate differentiation of the 3 PGPC lines into 3 0 hepatocytes that produce active enzymes. 
Utility of the resource -Mesodermal differentiation into kidney organoids and T-cells 1
To test the utility of PGPC lines as a resource, we made them available to pilot 2 users. Unlike mono-layer differentiations described above, human kidney organoids are 3 3D structures generated from iPSCs consisting of multiple cell types and resembling 4 early embryonic human kidney tissue (Morizane et al., 2015; Taguchi et al., 2014; 5 Takasato et al., 2015; Wu et al., 2018) . Kidney organoids were made from all three 6 PGPC lines according to the protocol described by Takasato et al., 2015 but with minor 7 modifications (e.g. feeder-free iPSC culture and omission of conditioned medium) 8 similar to those implemented in more recent publications (van den Berg et al., 2018; 9 Forbes et al., 2018) ( Fig. S2A ).
0
This protocol entailed a 7-day monolayer culture with directed differentiation 1 1 towards posterior streak mesoderm (PSM) and subsequently to anterior and posterior PIM and thus, fewer or more nephrons (Takasato et al., 2015) . For all experiments, we 1 7 made this factor switch on D5. During this course, the PSM marker T (brachyury) was 1 8 transiently induced followed by AIM marker GATA3 and PIM marker HOXD11 as 1 9 measured by qPCR and expression was normalized to iPSCs at D0 ( Fig. 4A ). After 2 0 seven days of monolayer differentiation, cells were aggregated by centrifugation and 2 1 transferred to Transwell membranes. Aggregates were pulsed with CHIR for one hour 2 2 and then treated with FGF9/heparin for five additional days. Shortly after aggregation, aggregates. mRNA level analysis (normalized to D7 pre-aggregated cells) showed the 2 5 induction of markers of different nephron segments, endothelial, and stromal cell 2 6 markers in D25 organoids ( Fig. 4A ). Immunofluorescence imaging of D18 cross- To evaluate the potential to generate hematopoietic stem/progenitor cells 1 (HSPCs) and T-cells, we compared the PGPC lines to iPSC11 (Alstem Cell 2 Advancements) in an embryoid body differentiation protocol described by Kennedy et 3 al., 2012 with feeder-free adaptation (Fig. S2B ). All three PGPC lines gave rise to 4 CD34+ hemogenic endothelial (HE) cells with a similar efficiency as iPSC11 cells (Fig. 5 4C), which were magnetic-activated cell sorted at D8 (Fig. S2C ). PGPC14 and 17 were 6 most enriched for CD34+ cells, which were then cocultured on OP9-DL4 cells to induce 7 a T cell differentiation program. Next, multi-colour flow cytometry was used to 8 simultaneously measure different cell populations at D8+14 and D8+42 to assess the 9 ability of HE-derived HSPCs to differentiate to T-lymphocytes, a hallmark of definitive whilst PGPC17 showed a more rapid transition (17%) compared to iPSC11 (53%). (TCR/CD3+). At this time point, the PGPC lines showed similar propensity as iPSC11 to 1 8 generate TCR alpha/beta (39-45%) cells, but only PGPC17 produced rare TCR 1 9 gamma/delta bearing (0.1%) cells. We conclude that PGPC lines differentiate into HE 2 0 cells that develop into into T-cells but with different differentiation kinetics that may 2 1 require line-specific protocol optimization.
2
Utility of the resource -Sensory neuron protocol optimization and subtype identification 2 3 PGPC17_11 was selected to optimize differentiation into peripheral sensory 2 4 neurons (PSNs) using a small molecule inhibitor protocol adapted from (Chambers et 2 5 al., 2012) ( Fig. 5A ). We found improved growth and survival with the addition of NGF at 2 6 D2 and using N2 media with the following composition: 47.5% DMEM/F12, 47.5% increased over time (p = 0.0001), as did the proportion responsive to the purinergic 1 9 receptor agonist ATP (p = 0.042). These results demonstrate that PGPC17 was 2 0 successfully differentiated into active neurons with a non-peptidergic nociceptor or 2 1 mechanoreceptor phenotype. To identify iPSC-specific variants we obtained whole genome sequences of each 2 4 PGPC line to compare to their respective donor blood sequences (Table 1) PGPC3_75 at low allelic fraction (4/22 reads), compatible with mosaicism (Table S2 ). We did not identify any other known pathogenic sequence variants in reprogrammed 1 cell lines. Three loss-of-function variants, although not associated with human disease, 2 were in genes with high haploinsufficiency scores and known function in embryonic 3 development (PGPC14_26: TRIM71 and FRMD4A, PGPC17_11: ROBO2, Table S3 ).
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For PGPC14_26, we also identified an intronic 16-kb-deletion of uncertain significance 5 in IL1RAPL1, a gene associated with impaired synaptogenesis and neurodevelopmental 6 deficits. Annotation of the PGP donor and cell-line derivative sequences will be 7 important as variant databases mature (Costain et al., 2018) . To edit a gene for cardiac phenotyping, we targeted a region of MYBPC3 where 1 0 frameshifts are associated with hypertrophic cardiomyopathy by using guide (g)RNAs 1 1 for CRISPR-Cas9 directed non-homologous end-joining. We nucleofected PGPC17_11 1 2 iPSCs with a pSpCas9(BB)-2A-Puro vector containing gRNA sequences targeting 1 3 MYPBC3 (Fig 6A) . Transfected cells were selected with puromycin treatment and 1 4 resistant colonies were isolated and expanded. A karyotypically normal sub-clone 1 5
bearing an apparent homozygous frameshift mutation was identified in the MYBPC3_KO line by Sanger sequencing (Fig. 6A/B ). To characterize genetic changes, 1 7
we performed WGS. On-target compound heterozygote MYBPC3 frameshifts were 1 8
shown to be an 8-bp insertion at chr11:47,359,282insGTGCAGGA, and a large >260 bp 1 9 insertion at the same position in the other allele. This insertion did not map to the 2 0 human genome and was not detected using our PCR-based sequencing due to the size 2 1 of the insertion. To characterize potential off-target effects in the MYBPC3_KO cells, we 2 2 first used benchling.com's prediction tool to identify the top 49 off-target sites. We 12169689) were found (Table 1) . None of these variants were likely pathogenic, similar To examine the consequences of the frameshifts on MYBPC3 protein, we 3 0 generated CMs as described in Figure 3 and collected protein lysates from PGPC17 Since we found that all our iPSC lines have pre-existing and/or novel variants of 1 1 potential concern when considering experiments for different lineages, we analyzed HPSI0314i.hoik_1 and HPSI0314i.sojd_3). Across all five samples, 89-96% of the 1 5 genome was covered at least 20x (quality metrics in Table S4 ). We interpreted likely Two likely pathogenic variants were found in kolf_2 and one in sojd_3 that were connective tissue, such as in the vascular system, skin, intestine, lung, and uterus, and were present in the donor genomes, or arose during reprogramming, and could 5 therefore be mosaic. We also identified several loss-of-function variants of uncertain 6 significance in constrained genes in hoik_1 and kucg_2, mostly with known functions in 7 early development (as in PTK2, ZNF398, UBE3C, CDC37, TNS3; Table S3 ) and many 8 VUS (Supp Excel files). We did not identify pathogenic or likely pathogenic variants in 9 wibj_2 which suggests it is the variant-preferred line amongst this subset. Apart from their versatility, the main advantage of these blood-derived footprint-2 0 free lines is the clinical annotation of potentially disease-associated variants that may donors' genomes allowed predictions on how to prioritize control lines for use as tissue 2 9 specific controls. For example, as PGPC3 and PGPC14 had variants that could 3 0 1 5 predispose to altered cardiac channel function, PGPC17 was deemed to be the 1 preferred line for the study of cardiac disease. PGPC3 however was preferred for 2 neurological disorders.
3
WGS has previously determined that iPSC lines have variants that differ from 4 those in the donor. Our WGS data reveals that the reprogrammed lines have more than 5 a thousand new SNVs each, whereas only 1 new CNV (15.6 kb) was detected likely due 6 to prior selection for normal karyotype. Most variants were of uncertain significance, 7 with three new variants of potential concern in PGPC14_26 ( Table S3 ). Genome 8 sequencing of the MYBPC3 KO line showed more than 900 additional SNVs compared 9 to the unedited iPSC line. None of the new variants were near potential gRNA cut sites, 1 0 suggesting they were not off-target and were indeed de novo mutations. These 1 1 analyses highlight that iPSC lines harbor variants of potential concern that are not found 1 2 in the donor blood. Moreover, our annotation of 5 healthy control lines from the HipSci 1 3 consortium discovered likely pathogenic variants in 2 lines and additional loss-of-1 4 function variants in constrained genes in 2 other lines, leaving only wibj_2 as a 1 5 preferred healthy control line. We propose that clinical annotation of WGS data is an 1 6 important quality control measure of iPSC lines, and that its expanded use will identify 1 7 additional variant-preferred lines to use as healthy controls for disease modeling. for variability in reprogramming. To account for 1000-2000 novel variants in each line 2 0 compared to the parental genome, this study provides another rationale for studying 2 1 multiple lines from each individual. With this in mind, we generated a resource of 4-5 2 2 iPSC lines each from two males and two females, all with standard pluripotency 2 3 characterization available. We additionally performed multilineage directed 2 4 differentiation on a single line from three individuals, assuming that single lines from 3-4 2 5 individuals can account for inter-individual variability. One highly characterized line is 2 6 therefore available from three PGPC participants, and preferred lines are likely to be of 2 7 high utility for gene editing studies that compare the phenotype of isogenic cells.
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